ArticleFrontiers in pharmacology2020
Antagonism of CGRP Signaling by Rimegepant at Two Receptors.
Article in Frontiers in pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.
- Systematic review and meta-analysis on the efficacy and safety of rimegepant for migraine.Frontiers in neurologyPooled it
- Emerging pharmacological targets in migraine therapy: CGRP and beyond.Frontiers in pharmacology · 2026Review
- Comparing eptinezumab with onabotulinumtoxinA in the treatment of chronic migraine: a real-world evidence study.The journal of headache and pain · 2025Article
- Rimegepant in airplane headache treatment: a case report.Journal of medical case reports · 2025Article
- Efficacy and safety of mAbs anti-CGRP/CGRP R (eptinezumab and erenumab) or atogepant in combination with onabotulinumtoxinA in refractory chronic migraine: a clinical trial protocol.Pain management · 2025Article
- Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines.Signal transduction and targeted therapy · 2025Review
- A Review of Amylin Peptide Receptor Activators for Obesity Pharmacotherapy.Current drug targets · 2025Review
- Combining treatments for migraine prophylaxis: the state-of-the-art.The journal of headache and pain · 2024Review
- Differential expression of components of the CGRP-receptor family in human coronary and human middle meningeal arteries: functional implications.The journal of headache and pain · 2024Article
- Pituitary cyclase-activating polypeptide targeted treatments for the treatment of primary headache disorders.Annals of clinical and translational neurology · 2024Review
- Pharmacological characterisation of erenumab, Aimovig, at two calcitonin gene-related peptide responsive receptors.British journal of pharmacology · 2024Article
- What to do with non-responders to CGRP(r) monoclonal antibodies: switch to another or move to gepants?The journal of headache and pain · 2023Article
- Calcitonin/PACTrends in pharmacological sciences · 2023Review
- Mode and site of action of therapies targeting CGRP signaling.The journal of headache and pain · 2023Review
- Blocking the CGRP Receptor: Differences across Human Vascular Beds.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Future targets for migraine treatment beyond CGRP.The journal of headache and pain · 2023Review
- CGRP physiology, pharmacology, and therapeutic targets: migraine and beyond.Physiological reviews · 2023Review
- Review
- New characterization of dihydroergotamine receptor pharmacology in the context of migraine: utilization of a β-arrestin recruitment assay.Frontiers in neurology · 2023Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The "gepants" are a class of calcitonin gene-related peptide (CGRP) receptor antagonist molecules that have been developed for the prevention and treatment of migraine. Rimegepant is reported to act at the CGRP receptor, has good oral bioavailability, and has had positive clinical trial results. However, there is very little data available describing its receptor pharmacology. Importantly, rimegepant activity at the AMY
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.